Company intelligence / Profile preview

Tribune Company

Oslo, Norway

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Tribune Therapeutics is a preclinical-stage biopharmaceutical company dedicated to developing novel therapies for high-need fibrotic diseases. The company focuses on targeting the CCN family of proteins, particularly Connective Tissue Growth Factor (CCN2/CTGF), to modulate the biological pathways driving tissue scarring and organ failure. Headquartered in Oslo, Norway, Tribune leverages deep expertise in fibrosis biology to advance a pipeline of monoclonal antibodies. Its lead programs aim to treat chronic conditions such as kidney, liver, and lung fibrosis. The company is backed by prominent life science investors including HealthCap and Novo Holdings.

Therapeutic areas: NephrologyPulmonologyGastroenterology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Tribune Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tribune Company.

Explore the full profile